Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 7:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 385 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Iodine Clear all
Terminated Phase 3 Interventional Results available

International Study to Determine if AdreView Heart Function Scan Can be Used to Identify Patients With Mild or Moderate Heart Failure (HF) That Benefit From Implanted Medical Device

NCT02656329
View directory record Official record
Conditions
Heart Failure
Interventions
Iobenguane I -123 Injection, Implantable Cardioverter Defibrillator, Thyroid blocking
Drug · Device
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
395 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
29
States / cities
Birmingham, Alabama • Bakersfield, California • La Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 22, 2019 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dental Office Prevention Strategies for Children

NCT02004990
View directory record Official record
Conditions
Dental Plaque
Interventions
Single cleansing procedure of 10% Povidone Iodine
Procedure
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 13 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Tracheostomy Granulomas

NCT02116608
View directory record Official record
Conditions
Granuloma, Tracheostomy
Interventions
Betadine, Silver Nitrate, Hydrocortisone Butyrate Cream, 1.0%
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 17 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 13, 2021 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Not applicable Interventional Results available

Trial of Integrated Smoking Cessation, Exercise and Weight Management in Serious Mental Illness: TRIUMPH

NCT02424188
View directory record Official record
Conditions
Mental Illness
Interventions
TRIIUMPH Intervention
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 1Phase 2 Interventional Results available

PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

NCT04347954
View directory record Official record
Conditions
COVID-19
Interventions
Povidone-Iodine 2%, Povidone-Iodine 0.5%, Isotonic saline 0.9%
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Oct 24, 2026, 7:59 PM EDT
Recruiting Phase 2 Interventional

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

NCT00107289
View directory record Official record
Conditions
Neuroblastoma, Pheochromocytoma
Interventions
iobenguane I 131
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 29, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 2 Interventional

Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia

NCT00003868
View directory record Official record
Conditions
Leukemia
Interventions
cyclophosphamide, methotrexate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, iodine I 131 monoclonal antibody BC8, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
2 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 24, 2010 · Synced Oct 24, 2026, 7:59 PM EDT
Recruiting Phase 4 Interventional

Skin Preparation for Elective Foot and Ankle Surgery

NCT05401292
View directory record Official record
Conditions
Microbial Colonization, Foot and Ankle Disorders
Interventions
Hibiclens, Isopropyl Alcohol 70% Topical Application Solution
Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 3 Interventional

Epithelium-On Corneal Cross-linking in Subjects 8 to 45 Years of Age With Keratoconus

NCT06100952
View directory record Official record
Conditions
Keratoconus
Interventions
Riboflavin and Sodium Iodide solution and Ultraviolet-A treatment, Placebo and sham treatment
Combination Product
Lead sponsor
Epion Therapeutics
Industry
Eligibility
8 Years to 45 Years
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
12
States / cities
Scottsdale, Arizona • Tucson, Arizona • Murrieta, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Not applicable Interventional

High-Resolution Anoscopy Perceived Discomfort Study

NCT04083053
View directory record Official record
Conditions
Pain, Anal Cancer
Interventions
Perianal Exam, high-resolution anoscopy (HRA) with biopsy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Oct 24, 2026, 7:59 PM EDT
Withdrawn Not applicable Interventional

Prevention of Surgical Site Infection After Cesarean Delivery

NCT02027324
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chlorhexidine-alcohol group, Povidone-Iodine Group
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04505566
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 2 Interventional Results available

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

NCT00729157
View directory record Official record
Conditions
Recurrent Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma, Stage III Thyroid Gland Papillary Carcinoma, Stage IV Thyroid Gland Follicular Carcinoma, Stage IV Thyroid Gland Papillary Carcinoma
Interventions
Fludeoxyglucose F-18, Laboratory Biomarker Analysis, Pharmacological Study, Positron Emission Tomography, Ziv-Aflibercept
Radiation · Other · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 15, 2017 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study

NCT05206331
View directory record Official record
Conditions
Breast Cancer
Interventions
contrast enhanced mammography, Iodinated Contrast Media (ICM)
Device · Drug
Lead sponsor
Margarita Louise Zuley
Other
Eligibility
30 Years and older · Female only
Enrollment
2,089 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Suspended Not applicable Interventional

Personalized Treatment in Thyroid Disorders

NCT03517579
View directory record Official record
Conditions
Thyroid Cancer, Graves Disease
Interventions
Cervical Collar Therapy Indicator (COTI)
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Chlorhexidine Gluconate Versus Povidone Iodine at Cesarean Delivery: a Randomized Controlled Trial

NCT01975805
View directory record Official record
Conditions
Pregnancy, Cesarean Section
Interventions
Chlorhexidine Gluconate, Povidone Iodine
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2013 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 4 Interventional Results available

Visibility of Site Marking for Surgical Time Out With Two Different Skin Preparation Solutions

NCT00739583
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
CHG 2% w/v and IPA 70% v/v, Iodophor 0.7% and IPA 74% w/w
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Oct 24, 2026, 7:59 PM EDT
Recruiting Phase 3 Interventional

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

NCT03126916
View directory record Official record
Conditions
Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Busulfan, Carboplatin, Cisplatin, Computed Tomography, Cyclophosphamide, Dexrazoxane Hydrochloride, Dinutuximab, Doxorubicin Hydrochloride, Echocardiography Test, Etoposide Phosphate, External Beam Radiation Therapy, Iobenguane I-123, Iobenguane I-131, Isotretinoin, Lorlatinib, Magnetic Resonance Imaging, Melphalan Hydrochloride, Multigated Acquisition Scan, Positron Emission Tomography, Sargramostim, Therapeutic Conventional Surgery, Thiotepa, Topotecan Hydrochloride, Vincristine Sulfate
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
365 Days to 30 Years
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 121 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Phase 1 Interventional

Convection-Enhanced Delivery of 124I-Omburtamab for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

NCT01502917
View directory record Official record
Conditions
Brain Cancer, Brain Stem Glioma
Interventions
Radioactive iodine-labeled monoclonal antibody omburtamab, External Beam Radiotherapy
Drug · Radiation
Lead sponsor
Y-mAbs Therapeutics
Industry
Eligibility
2 Years to 21 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 19, 2023 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding

NCT04478019
View directory record Official record
Conditions
COVID-19, SARS-CoV 2
Interventions
10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
245 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2022 · Synced Oct 24, 2026, 7:59 PM EDT
Active, not recruiting No phase listed Observational

A Diagnostic Test for Dementia With Lewy Bodies

NCT05479552
View directory record Official record
Conditions
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
Interventions
Syn-One Test
Diagnostic Test
Lead sponsor
CND Life Sciences
Other
Eligibility
50 Years to 85 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
12
States / cities
Scottsdale, Arizona • La Jolla, California • Englewood, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 24, 2026, 7:59 PM EDT
Recruiting Not applicable Interventional

Influence of Antiseptic Washes on Wound Healing Complications After THA

NCT07104084
View directory record Official record
Conditions
Hip Osteoarthritis, Avascular Necrosis of Femur Head
Interventions
lavage chlorhexidine, lavage povidone-iodine
Device
Lead sponsor
F. Johannes Plate
Other
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Monroeville, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 24, 2026, 7:59 PM EDT
Withdrawn Phase 3 Interventional

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

NCT00319332
View directory record Official record
Conditions
Lymphoma, Small Cleaved-Cell, Follicular, Lymphoma, Large-Cell, Follicular, Lymphoma, Follicular, Lymphoma, Non-Hodgkin
Interventions
Ibritumomab Tiuxetan, Iodine I 131 Tositumomab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2021
U.S. locations
8
States / cities
Iowa City, Iowa • St Louis, Missouri • Buffalo, New York + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2015 · Synced Oct 24, 2026, 7:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pilot Study: Combined Molecular Breast Imaging/Ultrasound System for Diagnostic Evaluation of MBI-detected Lesions

NCT01806558
View directory record Official record
Conditions
Breast Cancer
Interventions
Molecular Breast Imaging
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
40 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 24, 2026, 7:59 PM EDT